Integrin Receptor Antagonist [EPC]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Integrin Receptor Antagonist [EPC] includes 2 drugs with a combined 138,172 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
138,172
Combined Reports
All Integrin Receptor Antagonist [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| VEDOLIZUMAB | ENTYVIO | 73,857 | 3,476 | 21,677 | 4.7% |
| NATALIZUMAB | TYRUKO | 64,315 | 3,140 | 17,879 | 4.9% |
Common Side Effects in Integrin Receptor Antagonist [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Off label use | 21,509 | 655 |
| Colitis ulcerative | 13,511 | 155 |
| Drug ineffective | 10,181 | 208 |
| Crohn's disease | 9,940 | 229 |
| Fatigue | 9,933 | 416 |
| Diarrhoea | 8,133 | 409 |
| Abdominal pain | 6,645 | 118 |
| Multiple sclerosis relapse | 6,490 | 96 |
| Malaise | 6,207 | 292 |
| Headache | 6,050 | 369 |